Current prospects of fluoroquinolones: pazufloxacin. A review; Современные возможности фторхинолонов: пазуфлоксацин

Fluoroquinolones (FQ) are one of the most valuable groups of antibacterial drugs in clinical practice. Ciprofloxacin and levofloxacin are drugs with the largest contribution to the structure of FQ consumption both in the Russian Federation and in the world. The widespread use of FQ in recent years has been accompanied by an intensive growth of antibiotic resistance of the main pathogens, including those from the ESKAPE group, which limits the possibilities of effective antibiotic therapy for a wide range of infectious diseases. In this situation, we have an attractive possibility of including a new FQ for the Russian pharmaceutical market, pazufloxacin, in the treatment regimens for patients with infectious diseases. This is a third-generation FQ, whose spectrum of antibacterial action, as has been demonstrated in the published studies, is close to that of the beta-lactam ABP ceftazidime. The studies considered in our narrative review indicate a high level of clinical efficacy and safety of this FQ, which suggests broad prospects for its use in the treatment of infectious diseases taking in account accelerated antibiotic resistance. © 2025 Elsevier B.V., All rights reserved.